Journal September 27, 2026 4 min read

What markers track the blood-brain barrier?

A research-supply overview of candidate markers and imaging readouts used to track blood-brain barrier integrity and permeability across clinical and preclinical models.

peptides-pro Editorial

The blood-brain barrier (BBB) is a selective interface formed by brain endothelial cells, pericytes, astrocytes, and the neurovascular unit. Markers used to track it fall into three broad classes: circulating proteins released or detected when barrier integrity is compromised, imaging readouts of permeability and contrast enhancement, and cellular or molecular indicators of endothelial senescence and neurovascular injury. No single marker is definitive; studies typically combine imaging, blood-based analytes, and tissue-based assays.

The work described below centres on receptor-mediated transcytosis (RMT) pathways — particularly transferrin receptor (TfR) and insulin-like growth factor 1 receptor (IGF1R) — as both delivery routes and functional handles for assessing BBB crossing and retention [4].

Research Studies

taVNS and markers of BBB permeability in radiation necrosis

A multi-centre, randomized, blinded trial is evaluating transcutaneous auricular vagal nerve stimulation (taVNS) in patients with radiation necrosis-related cerebral edema. Participants are assigned to treatment or sham arms. Both arms undergo imaging and collection of tissue and blood for assessment of changes in area of contrast enhancement and cerebral edema, inflammatory markers, and markers of BBB permeability [1].

Cerebrolysin and BBB injury after extended-window thrombectomy

In acute ischemic stroke caused by large-artery occlusion, endovascular thrombectomy can restore flow but some patients remain disabled. Ongoing injury to brain tissue, small vessels, and the BBB may contribute to incomplete recovery. A multicentre randomized trial is testing whether Cerebrolysin given after successful extended-window thrombectomy reduces brain tissue injury and supports recovery [3].

Dual-targeted antibodies and BBB retention

Receptor-mediated transcytosis via TfR shuttle systems has improved antibody delivery to the brain, but rapid clearance of TfR shuttles from the brain limits retention. A proposed approach combines binding to intra-brain proteins — myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, and chondroitin sulfate proteoglycan 5 — with binding to BBB proteins such as TfR and IGF1R, to sustain retention after crossing [4].

Circulating PlGF and BBB disruption in glioblastoma

In glioblastoma, angiogenesis is multifactorial and BBB disruption enables detection of circulating mediators. A prospective observational study of 54 patients with IDH-wildtype GBM analysed plasma samples at diagnosis and recurrence using a multiplex panel of angiogenesis mediators, and examined associations between circulating placental growth factor (PlGF) and clinical, radiological, molecular, and treatment-related variables [6].

Senescent brain endothelial cells and nanoparticle clearance

Brain endothelial cell (BEC) senescence is implicated in age-related BBB dysfunction. Polymeric nanoparticles loaded with the senolytic agent Navitoclax were designed to be taken up by both proliferative and senescent BECs, but degraded only in senescent cells due to senescence-associated beta-galactosidase (SA-β-gal), releasing drug to induce cell death. The nanoparticles selectively eliminated senescent BECs in the reported model [8].

Ketamine, astrocyte mitochondria, and BBB-adjacent signalling

Ketamine's antidepressant efficacy has classically been attributed to noncompetitive antagonism of the postsynaptic neuronal NMDA receptor, reducing excessive Ca²⁺ influx. More recent evidence suggests additional physiological changes, including preconditioning of astrocyte mitochondria and upregulation and efflux of adenosine, humanin, and melatonin [5]. These findings relate to astrocyte and neurovascular function rather than to a direct BBB permeability marker.

Circadian disruption and neurovascular pathways in Alzheimer's disease

A narrative review synthesizes literature on circadian dysfunction in Alzheimer's disease, including interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis. Disrupted circadian-regulated pathways include BMAL1–SIRT1 and NF-κB–NLRP3 signalling [7]. These mechanisms are relevant to neurovascular and barrier-adjacent biology but are not themselves validated BBB markers.

Protein-energy wasting and systemic anabolic resistance in CKD

In advanced chronic kidney disease, protein-energy wasting drives morbidity and mortality. A proposed 'sensitize-then-feed' framework addresses a nutritional paradox in which CKD-associated cachexia shows systemic anabolic resistance, rendering standard nutritional interventions — including oral supplements and intradialytic parenteral nutrition — often insufficient [2]. This work concerns systemic metabolic signalling rather than a direct BBB marker.

Comparison of marker categories

Marker category	Example readout	Model / population	Source
Imaging	Area of contrast enhancement, cerebral edema	Patients with radiation necrosis-related cerebral edema	[1]
Circulating protein	Plasma PlGF	IDH-wildtype glioblastoma patients	[6]
Target engagement	TfR and IGF1R binding; intra-brain protein binding	Preclinical antibody delivery models	[4]
Cellular senescence	SA-β-gal activity in brain endothelial cells	In vitro / preclinical nanoparticle model	[8]

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research only. We do not provide dosing, diagnostic, or medical guidance, and nothing on this page should be used to evaluate or treat a personal health condition. Anyone considering a compound for themselves should speak to a licensed clinician.